Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business and operational goals in press releases published: On January 9, 2025 in a press release titled "Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment"On January 23, 2025 in a press rele

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026.Blinded baseline characteristics align with pre-specified target population and are consistent with Phase 2b UC trial participant characteristics Cash run

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC

Abivax Announces Full Year 2024 Financial Results •        Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis ("UC") expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:30 AM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax's Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology

Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar. Monday, March 24, 2025 (after US Market closes) 2024 Annual Business and Financial Report (as of December 31, 2024) Press ReleaseUniversal Registration Document (Euronext)Annual Report on Form 20-F Monday, June 2, 2025 (after US Market closes) 2025 Q1 Financial Results (as of March 31, 2025) Press ReleaseReport on Form 6-K Friday, June 6, 2025         

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational, orally administered, once-daily small molecule] in clinical development for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at The European Crohn's and Colitis Organ

Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-

PARIS, France, June 4, 2024 – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the "General Meeting"), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the 2023 financial year, the compensation poli

Sofinnova Investments, a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor. In this role, he will be advising Sofinnova's portfolio companies on corporate and financial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312683597/en/Troy Ignelzi, Executive Advisor, Sofinnova Investments (Photo: Business Wire) Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors. He is currently Chief Financial Officer at Rapport Therapeutics, a clinical-stage biotechnology company leveraging

Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality. Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance. She has helped bring over 30 drugs to market across multiple therapeutic areas, including

Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $12.00

JMP Securities initiated coverage of Abivax SA with a rating of Mkt Outperform and set a new price target of $33.00

Laidlaw initiated coverage of Abivax SA with a rating of Buy and set a new price target of $48.00

BTIG Research initiated coverage of Abivax SA with a rating of Buy and set a new price target of $43.00

Piper Sandler initiated coverage of Abivax SA with a rating of Overweight and set a new price target of $42.00

Guggenheim initiated coverage of Abivax SA with a rating of Buy and set a new price target of $50.00

Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $15.00

Leerink Partners initiated coverage of Abivax SA with a rating of Outperform and set a new price target of $20.00

SC 13G/A - Abivax S.A. (0001956827) (Subject)

SC 13G - Abivax S.A. (0001956827) (Subject)